OTCPK:MDXL

Stock Analysis Report

Executive Summary

MediXall Group, Inc., together with its subsidiaries, operates healthcare marketplace platform in the United States.

Risk Analysis

Earnings have declined by -42.4% per year over past 5 years

Has less than 1 year of cash runway

Shares are highly illiquid

Makes less than USD$1m in revenue ($3K)

+ 2 more risks


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has MediXall Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MDXL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

MDXL

-1.1%

US Healthcare Services

0.6%

US Market


1 Year Return

11.7%

MDXL

26.5%

US Healthcare Services

20.8%

US Market

Return vs Industry: MDXL underperformed the US Healthcare Services industry which returned 26.5% over the past year.

Return vs Market: MDXL underperformed the US Market which returned 20.8% over the past year.


Shareholder returns

MDXLIndustryMarket
7 Day0%-1.1%0.6%
30 Day29.1%1.8%2.5%
90 Dayn/a2.2%4.9%
1 Year11.7%11.7%26.7%26.5%23.5%20.8%
3 Yearn/a89.2%88.5%46.5%37.0%
5 Yearn/a64.4%62.9%64.6%46.5%

Price Volatility Vs. Market

How volatile is MediXall Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MediXall Group undervalued compared to its fair value and its price relative to the market?

985.43x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MDXL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MDXL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MDXL is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: MDXL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDXL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDXL is overvalued based on its PB Ratio (985.4x) compared to the US Healthcare Services industry average (3.9x).


Next Steps

Future Growth

How is MediXall Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MediXall Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of MDXL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access MediXall Group's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has MediXall Group performed over the past 5 years?

-42.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MDXL is currently unprofitable.

Growing Profit Margin: MDXL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDXL is unprofitable, and losses have increased over the past 5 years at a rate of -42.4% per year.

Accelerating Growth: Unable to compare MDXL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDXL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-0.2%).


Return on Equity

High ROE: MDXL has a negative Return on Equity (-1394.83%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is MediXall Group's financial position?


Financial Position Analysis

Short Term Liabilities: MDXL's short term assets ($50.7K) do not cover its short term liabilities ($297.4K).

Long Term Liabilities: MDXL's short term assets ($50.7K) do not cover its long term liabilities ($64.2K).


Debt to Equity History and Analysis

Debt Level: MDXL is debt free.

Reducing Debt: MDXL has not had any debt for past 5 years.


Balance Sheet

Inventory Level: MDXL has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if MDXL's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDXL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MDXL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -26% each year


Next Steps

Dividend

What is MediXall Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage0.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MDXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MDXL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDXL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDXL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDXL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of MediXall Group's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Neil Swartz (57yo)

3yrs

Tenure

US$150,000

Compensation

Mr. Neil Swartz, CPA, serves as the Interim Chief Executive Officer at MediXall Group, Inc since 2016 and served as its President. Mr. Swartz has been the Interim Chief Executive Officer and Interim Presid ...


Management Age and Tenure

2.0yrs

Average Tenure

57yo

Average Age

Experienced Management: MDXL's management team is considered experienced (2 years average tenure).


Board Age and Tenure

1.8yrs

Average Tenure

60yo

Average Age

Experienced Board: MDXL's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.1%.


Management Team

  • Tim Hart (60yo)

    CFO, Treasurer

    • Tenure: 7yrs
    • Compensation: US$250.00k
  • Neil Swartz (57yo)

    Interim Chief Executive Officer

    • Tenure: 3yrs
    • Compensation: US$150.00k
  • Michael Swartz (28yo)

    President of Medixall.com

    • Tenure: 0.7yrs
  • Guy Connor (57yo)

    Executive Vice President

    • Tenure: 0yrs
  • John Howard

    Senior Vice President of Laboratory Services

    • Tenure: 1yrs

Board Members

  • Noel Guillama-Alvarez (60yo)

    Chairman of the Board

    • Tenure: 3yrs
  • Tim Hart (60yo)

    CFO, Treasurer

    • Tenure: 7yrs
    • Compensation: US$250.00k
  • Howard Braverman (72yo)

    Member of Strategic Advisory Board

    • Tenure: 0.8yrs
  • Steven Gass

    Member of Strategic Advisory Board

    • Tenure: 1.3yrs
  • Winston Marshall (54yo)

    Member of Medical Advisory Board

    • Tenure: 1.8yrs
  • John DeLuca

    Member of Medical Advisory Board

    • Tenure: 1.8yrs
  • Kenneth Janson

    Member of Medical Advisory Board

    • Tenure: 1.8yrs
  • Benjamin Frosch

    Member of Strategic Advisory Board

    • Tenure: 1.3yrs
  • Ellis Ellis

    Member of Advisory Board

    • Tenure: 0.8yrs

Company Information

MediXall Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MediXall Group, Inc.
  • Ticker: MDXL
  • Exchange: OTCPK
  • Founded: 1998
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$194.571m
  • Shares outstanding: 75.71m
  • Website: https://www.medixall.com

Number of Employees


Location

  • MediXall Group, Inc.
  • 2929 East Commercial Boulevard
  • Suite PH-D
  • Fort Lauderdale
  • Florida
  • 33308
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDXLOTCPK (Pink Sheets LLC)YesCommon Stock USUSDDec 2016

Biography

MediXall Group, Inc., together with its subsidiaries, operates healthcare marketplace platform in the United States. The company’s cloud- based MediXall.com platform that connects patients with healthcare  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/14 01:26
End of Day Share Price2019/12/11 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.